These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21079818)

  • 1. Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
    Renke M; Tylicki L; Rutkowski P; Neuwelt A; Larczyński W; Ziętkiewicz M; Aleksandrowicz E; Lysiak-Szydłowska W; Rutkowski B
    Acta Biochim Pol; 2010; 57(4):547-52. PubMed ID: 21079818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
    Dogra G; Irish A; Chan D; Watts G
    Am J Kidney Dis; 2007 Jun; 49(6):776-85. PubMed ID: 17533020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
    Mose FH; Larsen T; Jensen JM; Hansen AB; Bech JN; Pedersen EB
    Scand J Clin Lab Invest; 2014 Jan; 74(1):8-19. PubMed ID: 24256611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes.
    Paulsen L; Matthesen SK; Bech JN; Starklint J; Pedersen EB
    J Clin Pharmacol; 2010 Jul; 50(7):816-22. PubMed ID: 20056802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans.
    Paulsen L; Holm C; Bech JN; Starklint J; Pedersen EB
    Nephrol Dial Transplant; 2008 May; 23(5):1556-61. PubMed ID: 18065809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency.
    Juncos LI; Martín FL; Baigorria ST; Pasqualini ME; Fiore MC; Eynard AR; Juncos LA; García NH
    Nutrition; 2012 Sep; 28(9):e23-8. PubMed ID: 22698702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
    Mackie FE; Rosenberg AR; Harmer JA; Kainer G; Celermajer DS
    Acta Paediatr; 2010 Mar; 99(3):457-9. PubMed ID: 20050832
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
    Ponte B; Bourquin V; Stoermann-Chopard C
    Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
    Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
    Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
    Campese VM
    Clin Exp Nephrol; 2014 Apr; 18(2):291-5. PubMed ID: 24535025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin (Lipitor).
    Tucker G
    Conn Med; 1998 May; 62(5):283-5. PubMed ID: 9639958
    [No Abstract]   [Full Text] [Related]  

  • 15. Atorvastatin ameliorates contrast medium-induced renal tubular cell apoptosis in diabetic rats via suppression of Rho-kinase pathway.
    Su J; Zou W; Cai W; Chen X; Wang F; Li S; Ma W; Cao Y
    Eur J Pharmacol; 2014 Jan; 723():15-22. PubMed ID: 24445019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin ameliorates tubulointerstitial fibrosis and protects renal function in chronic partial ureteral obstruction cases.
    Fitzgerald JP; Chou SY; Franco I; Mooppan UM; Kim H; Saini R; Gulmi FA
    J Urol; 2009 Oct; 182(4 Suppl):1860-8. PubMed ID: 19692013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic evaluation of gene expression changes in major target organs induced by atorvastatin.
    Kato N; Liang YQ; Ochiai Y; Jesmin S
    Eur J Pharmacol; 2008 Apr; 584(2-3):376-89. PubMed ID: 18295756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
    Kiberd BA
    Nat Clin Pract Nephrol; 2006 Jul; 2(7):354-5. PubMed ID: 16932460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.